Novo Nordisk beats expectations – upgrades outlook

Pharmaceutical company Novo Nordisk increased its net result in Q1 compared with the same period last year, thereby beating analyst expectations. Now, it's upgrading its outlook for 2021.

Photo: Novo Nordisk Pharmatech/PR

In the first three months of the year, Danish pharmaceutical company Novo Nordisk's net result increased steadily, while its top line has landed at the same level as last year, according to the firm's interim report for Q1 which was published Monday morning.

The report also reveals that the firm plans to upgrade its outlook for 2021.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs